4 assets in Dermatomyositis

Therapeutic assets addressing Dermatomyositis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Dermatomyositis	National Cancer Institute (NCI)	P1	CC (43)
Ipilimumab Dermatomyositis	National Cancer Institute (NCI)	P1	CC (43)
Nivolumab Dermatomyositis	National Cancer Institute (NCI)	P1	CC (43)